Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Replaces Sanofi Partnership With Second Regeneron Tie-Up For RNAi Drugs

Executive Summary

Already partnered with Regeneron in NASH, Alnylam unveils a new R&D collaboration in eye, CNS and liver indications, after Alnylam and Sanofi end the research phase of their relationship.

Advertisement

Related Content

Deal Watch: Gilead To Use Insitro’s AI/Functional Genomics Tech For NASH Targets
Allergan Improves Safety Of Abicipar, But Not Enough Compared To Lucentis, Eylea
Regeneron's Less Frequent Eylea Dosing Makes Late Sprint Across FDA Finish Line
Alnylam Offers Flexible Value-Based Deals For Breakthrough RNAi Drug Onpattro
Alnylam and Regeneron Plan 50/50 Gene R&D Pact To Find NASH RNAi Drugs

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC125034

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel